TY - JOUR
T1 - Oral Polio Vaccine
T2 - Effect of Booster Vaccination One to 14 Years After Primary Series
AU - Bass, James W.
AU - Halstead, Scott B.
AU - Wiebe, Robert A.
AU - Fischer, Gerald W.
AU - Podgore, John K.
PY - 1978/5/26
Y1 - 1978/5/26
N2 - We studied the persistence of antibody after vaccination and the response to booster revaccination with trivalent oral polio vaccine (TOPV) administered at varied intervals after the primary series in a large group of children. Decline in antibody was related to intervals since last vaccination, and not to sex, age, age at primary vaccination, or type and number of previous administrations. Geometric mean titers of neutralizing antibody were 11.3 for type 1 and 8.0 for types 2 and 3 poliovirus when vaccine had been given within the previous year, declining to 3.2, 3.0, and 2.1 for types 1, 2, and 3 after nine years. Most children with an initial titer of 4 or less responded to revaccination with a fourfold or greater increase in titer of IgG. Geometric mean titers for all three types of polio dropped to this level when last TOPV administration had been five to six years or more. (JAMA 239:2252-2255, 1978).
AB - We studied the persistence of antibody after vaccination and the response to booster revaccination with trivalent oral polio vaccine (TOPV) administered at varied intervals after the primary series in a large group of children. Decline in antibody was related to intervals since last vaccination, and not to sex, age, age at primary vaccination, or type and number of previous administrations. Geometric mean titers of neutralizing antibody were 11.3 for type 1 and 8.0 for types 2 and 3 poliovirus when vaccine had been given within the previous year, declining to 3.2, 3.0, and 2.1 for types 1, 2, and 3 after nine years. Most children with an initial titer of 4 or less responded to revaccination with a fourfold or greater increase in titer of IgG. Geometric mean titers for all three types of polio dropped to this level when last TOPV administration had been five to six years or more. (JAMA 239:2252-2255, 1978).
UR - http://www.scopus.com/inward/record.url?scp=0018103832&partnerID=8YFLogxK
U2 - 10.1001/jama.1978.03280480044018
DO - 10.1001/jama.1978.03280480044018
M3 - Article
C2 - 206735
AN - SCOPUS:0018103832
SN - 0098-7484
VL - 239
SP - 2252
EP - 2255
JO - Journal of the American Medical Association
JF - Journal of the American Medical Association
IS - 21
ER -